http://purl.uniprot.org/citations/29444903 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
http://purl.uniprot.org/citations/29444903 | http://www.w3.org/2000/01/rdf-schema#comment | "CYP2C11 is involved in the metabolism of many drugs in rats. To assess the roles of CYP2C11 in physiology and drug metabolism, a CYP2C11-null rat model was generated using the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9method. A 2-base pair insertion was added to exon 6 of CYP2C11 in Sprague-Dawley rats. CYP2C11 was not detected by western blotting in liver microsomes of CYP2C11-null rats. No off-target effects were found at 11 predicted sites of the knockout model. The CYP2C11-null rats were viable and had no obvious abnormalities, with the exception of reduced fertility. Puberty in CYP2C11-null rats appeared to be delayed by ∼20 days, and the average litter size fell by 43%. Tolbutamide was used as a probe in this drug metabolism study. In the liver microsomes of CYP2C11-null rats, the Vmax and intrinsicclearance values decreased by 22% and 47%, respectively, compared with those of wild-type rats. The Km values increased by 47% compared with that of wild types. However, our pharmacokinetics study showed no major differences in any parameters between the two strains, in both males and females. In conclusion, a CYP2C11-null rat model was successfully generated and is a valuable tool to study the in vivo function of CYP2C11."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.org/dc/terms/identifier | "doi:10.1124/dmd.117.078444"xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/author | "Wang C."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/author | "Wei Y."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/author | "Zhang X."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/author | "Yang L."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/author | "Wang H."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/author | "Wang K."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/author | "Guo D."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/author | "Sui D."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/author | "Shan M."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/date | "2018"xsd:gYear |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/name | "Drug Metab Dispos"xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/pages | "525-531"xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/title | "Generation and Characterization of a CYP2C11-Null Rat Model by Using the CRISPR/Cas9 Method."xsd:string |
http://purl.uniprot.org/citations/29444903 | http://purl.uniprot.org/core/volume | "46"xsd:string |
http://purl.uniprot.org/citations/29444903 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/29444903 |
http://purl.uniprot.org/citations/29444903 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/29444903 |
http://purl.uniprot.org/uniprot/#_A0A0G2K879-mappedCitation-29444903 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29444903 |
http://purl.uniprot.org/uniprot/#_P08683-mappedCitation-29444903 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29444903 |
http://purl.uniprot.org/uniprot/A0A0G2K879 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/29444903 |
http://purl.uniprot.org/uniprot/P08683 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/29444903 |